Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Acadia Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The source filing: Acadia Pharmaceuticals’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333243
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Stock-based compensation | 31,638 | 25,720 |
| Amortization of premiums and accretion of discounts on investment securities | (503) | (3,652) |
| Amortization of intangible assets | 5,445 | 5,444 |
| Depreciation | 705 | 442 |
| Deferred Income Taxes | 9,679 | — |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | (29,188) | (8,766) |
| Interest and other receivables | 11,080 | (6,225) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Acadia Pharmaceuticals's D&A?
- Acadia Pharmaceuticals (ACAD) reported D&A of $434K in Q2 2026.
- How has Acadia Pharmaceuticals's D&A changed year-over-year?
- Acadia Pharmaceuticals's D&A increased by 103.8% year-over-year, from $213K to $434K.
- What is the long-term trend for Acadia Pharmaceuticals's D&A?
- Over 4 years (2021 to 2025), Acadia Pharmaceuticals's D&A has grown at a -21.0% compound annual growth rate (CAGR), from $2.24M to $871K.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Acadia Pharmaceuticals's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude